[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polycystic-ovarian-syndrome-pcos\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polycystic-ovarian-syndrome-pcos":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,53,79,115,140,168,189,210,232],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100053488","diaphragmatic-breathing-exercises-on-sleep-disorders-un-polycystic-ovarian-syndrome-100053488",false,"NCT07698925","Diaphragmatic Breathing Exercises on Sleep Disorders un Polycystic Ovarian Syndrome","Effect of Diaphragmatic Breathing on Sleep Disorders in Polycystic Ovarian Syndrome","Inclusion Criteria:\n\n* Women aged from 25-35 years old, Diagnosed with PCOS by gynecologist, diagnosis of PCOS will be based on the 2003 Rotterdam criteria.\n\n  * They have a Pittsburgh sleep quality index (PSQI) score greater than 5.\n  * Not participating in any physical exercise for the previous 3 months.\n  * They have an insomnia severity index score greater than 15.\n  * They have a fatigue severity scale score greater than 36.\n  * Ability to use internet and phone services\n\nExclusion Criteria:\n\n* • Women with autoimmune diseases and cancer.\n\n  * Women with neurological, mental, cardiopulmonary and musculoskeletal disorders.\n  * Pregnant or lactating women.\n  * Women who showed regular adherence to sleeping pills, antidepressants and hormonal replacement agents.\n  * Inability to perform diaphragmatic breathing due to physical limitations.\n  * Women who participate or receive any interventions that could affect their sleep","FEMALE","25 Years","35 Years",{"count":20,"type":21},54,"ESTIMATED","INTERVENTIONAL",[24],"NA","Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in females in reproductive age and not completely understood. Women with PCOS appear to have an increased frequency of sleep problems. Diaphragmatic Breathing (DB) exercises has positive effects on improving sleep quality. The purpose of this study will evaluate the effect of diaphragmatic breathing exercises on improving sleep quality in polycystic ovarian syndrome women.",[27,28,29,30,31,32],"Polycystic Ovarian Syndrome (PCOS)","Pittsburg Sleep Quality Index","Fatigue Severity Scale","Insomnia Severity Index","Diaphragmatic Breathing Exercise","Sleep Disorders",[34,35,36,37,38,39],"Polycystic ovary syndrome","Diaphragmatic breathing exercises","Sleep disorders","Pittsburg sleep quality index","Insomnia severity index","Fatigue severity scale","RECRUITING","2026-07-10",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":44},"2025-08-01",{"date":48,"type":21},"2026-08-30",{"name":50,"class":51},"Adly A Adam","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":52},"100632136","exercise-programs-in-women-with-pcos-100632136","NCT07509762","Exercise Programs in Women With PCOS","Investigation of the Effectiveness of a Digital Rehabilitation-Supported Combined Exercise Program in the Management of Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* Women aged 18-40 years diagnosed with PCOS according to the Rotterdam criteria (Rotterdam, 2003) and by a specialist physician.\n\nThe presence of at least two of the following three criteria will be considered sufficient for a diagnosis of PCOS according to the Rotterdam criteria: (i) history of irregular menstruation with oligo\u002Fanovulation, (ii) clinical and\u002For biochemical signs of hyperandrogenism, (iii) detection of polycystic ovary images on ultrasonography.\n\n* Having sufficient technological skills to participate in the treatment online (ability to use video conferencing applications)\n* Voluntary participation in the study\n\nExclusion Criteria:\n\n* Pregnant and breastfeeding women\n* Individuals with acute infections\n* Uncontrolled arrhythmia, hypertension, diabetes, and unstable angina pectoris\n* Impaired cooperation, orthopedic and neurological problems that may hinder assessment and program participation\n* Individuals with a history of lower extremity injury or surgery in the last six months\n* Individuals with class III obesity according to WHO classification (BMI \\> 40 kg\u002Fm2) (WHO, 2000)\n* Individuals receiving medical treatment for weight loss (liraglutide, semaglutide, orlistat, bupropion\u002Fnaltrexone, thizzpatide) or participating in a structured diet program during the study period\n* Individuals actively participating in another exercise program\n* Individuals taking antihypertensive, insulin-sensitizing, or hormonal contraceptive drugs in the last 3 months","18 Years","40 Years",{"count":63,"type":21},33,[24],"This study aims to investigate the effectiveness of a digital rehabilitation-supported combined exercise program in women with Polycystic Ovary Syndrome (PCOS). Participants aged 18-40 years will be randomly assigned to one of three groups: a digital rehabilitation group, a face-to-face exercise group, and a physical activity counseling group. The intervention will last 8 weeks, with exercise performed three times per week. Outcomes will include DNA methylation, hormonal and metabolic parameters, anthropometric measurements, body composition, muscle strength, basal metabolic rate, physical activity level, quality of life, menstrual cycle regularity, exercise adherence and satisfaction.",[27],[68],"PCOS, Digital rehabilitation, combined exercise, DNA methylation","NOT_YET_RECRUITING","2026-06-16",{"date":72,"type":44},"2026-06-17",{"date":74,"type":21},"2026-09-01",{"date":76,"type":21},"2027-03-25",{"name":78,"class":51},"Biruni University",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":52},"100638756","theta-healing-based-intervention-in-women-with-polycystic-ovary-syndrome-100638756","NCT07630441","Theta Healing-Based Intervention in Women With Polycystic Ovary Syndrome","The Effect of a Theta Healing-Based Intervention on Fertility Anxiety, Body Self-Compassion, and Body Image in Women Diagnosed With Polycystic Ovary Syndrome: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 18-45 years\n* Diagnosed with Polycystic Ovary Syndrome (PCOS)\n* Able to read and understand Turkish\n* Voluntary participation in the study\n* Access to a smartphone and internet connection\n\nExclusion Criteria:\n\n* Diagnosed psychiatric disorder\n* Participation in another psychological intervention program\n* Any health condition preventing participation in the intervention sessions\n* Incomplete questionnaire responses","45 Years",{"count":88,"type":21},142,[24],"This randomized controlled study aims to evaluate the effect of a Theta Healing-based intervention on fertility concerns, self-compassion, and body image in women diagnosed with Polycystic Ovary Syndrome (PCOS). Participants will be randomly assigned to intervention and control groups. The intervention group will receive a structured 5-day Theta Healing-based online intervention program, while the control group will continue routine care. Outcome measures will be assessed at baseline and 6 weeks after the intervention.",[27,92,93],"Infertility","Psychological Stress",[95,96,97,98,99,100,101,102,103,104,105],"PCOS","POLYCYSTIC OVARY SYNDROME","THETA HEALING","SELF-COMPASSION","BODY IMAGE","COMPLEMENTARY THERAPY","MEDITATION","REPRODUCTIVE HEALTH","Women's Health","Mind-Body Intervention","fertility anxiety","2026-06-03",{"date":108,"type":44},"2026-06-05",{"date":110,"type":21},"2026-06-08",{"date":112,"type":21},"2026-09-15",{"name":114,"class":51},"Ankara Medipol University",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":121,"maxAge":86,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":52},"100628281","phase-1-metformin-versus-myo-inositol-in-the-management-of-polycystic-ovarian-disease-a-comparative-study-100628281","NCT07459595","Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study","Inclusion Criteria:\n\n* Married or unmarried\n* Diagnosed with PCOS (females presenting with compliant of irregular cycle for \\>3 months, with hirsutism, acne, presence of polycystic ovaries detected on ultrasound ).\n\nExclusion Criteria:\n\n* Females already taken or taking PCOS treatment (on medical record)\n* Females already enrolled in another trial program\n* Females already taking trial drugs\n* Females with chronic diabetes (BSR\\>200 mg\u002Fdl), hypertension (BP≥140\u002F90mmHg)\n* Females with PCOS along with gestational sac (on ultrasound)\n* Females allergic to any content of trial drugs (on history)","16 Years",{"count":123,"type":21},60,[125],"PHASE1","In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and\u002For anovulation, clinical and\u002For biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound.\n\nThe objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.",[27],[129,130,27],"Metformin","Myo-inositol","2026-03-05",{"date":133,"type":44},"2026-03-10",{"date":135,"type":21},"2026-05-01",{"date":137,"type":21},"2026-07-31",{"name":139,"class":51},"Fatima Tariq",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":147,"sex":16,"minAge":148,"maxAge":18,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":4},"100578167","time-restricted-feeding-model-in-women-with-polycystic-ovary-syndrome-100578167","NCT06807775","Time Restricted Feeding Model in Women With Polycystic Ovary Syndrome","Effects of Time-Restricted Feeding Pattern (16:8) on Metabolic Variables and Appetite Related Gastrointestinal Hormones in Women With Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* For study groups of women diagnosed with polycystic ovary syndrome (PCOS)\n\n  * Aged between 19 and 35 years, with a diagnosis of PCOS\n  * No chronic diseases diagnosed by a physician, other than PCOS\n  * Body mass index (BMI) between 25 and 40 kg\u002Fm²\n  * No use of oral contraceptives, insulin sensitizers, or anti-androgen medications in the last three months\n* For the healthy control group\n\n  * Aged between 19 and 35 years\n  * No diagnosis of chronic diseases\n  * Body mass index (BMI) between 25 and 40 kg\u002Fm²\n  * No use of oral contraceptives, insulin sensitizers, or anti-androgen medications in the last three months\n\nExclusion Criteria:\n\n* For all study groups:\n\n  * Being in the menopause, pregnancy, or lactation period\n  * Having a diagnosis of any chronic disease (e.g., hypertension, diabetes mellitus, cardiovascular disease, etc.) other than PCOS, as determined by a physician\n  * Having hyperprolactinemia, congenital adrenal hyperplasia, androgen-secreting tumors, thyroid disorders, Cushing's syndrome, hepatic or renal dysfunction\n  * Using antihyperlipidemic, antihypertensive, or glucocorticoid medications\n  * Following any specific dietary treatment",true,"19 Years",{"count":150,"type":21},45,[24],"This study aims to evaluate the effects of a 16:8 time-restricted feeding (TRF) model on anthropometric, metabolic, and hormonal parameters in women with polycystic ovary syndrome (PCOS). In addition, the study will assess participants' food preferences, nutrient intake, and gastrointestinal hormone responses, alongside serum glucose, insulin, and glucagon levels, during ad libitum breakfast meals served at the beginning and end of the intervention.\n\nThe study consists of three groups: women with PCOS following a 16:8 TRF model for 12 weeks, women with PCOS following an energy-restricted diet for 12 weeks, and healthy women following a 16:8 TRF model for 12 weeks. Women aged 18-40, with PCOS based on the Rotterdam criteria, will be included in the PCOS groups, while those without PCOS-related symptoms will form the control group. Exclusion criteria include pregnancy, lactation, use of hormonal medications, and the presence of comorbidities such as diabetes or severe liver\u002Fkidney dysfunction.\n\nParticipants in the TRF groups will consume their daily caloric intake within an 8-hour eating window, fasting for the remaining 16 hours, while the energy-restricted group will follow a balanced diet without timing restrictions. Adherence to the dietary interventions will be monitored through weekly 24-hour dietary records. At baseline, participants will complete a demographic questionnaire, receive nutritional education for their nutritional plan, and undergo assessments for anthropometric and blood pressure measurements, sleep quality, food cravings, and physical activity. Biochemical analyses will evaluate thyroid and sex hormones, electrolytes, liver enzymes, lipid profiles, and hemograms. Additionally, all participants will wear smart wristbands (FitBit Charge 5) throughout the study to track sleep and physical activity.\n\nAt the beginning and end of the study, participants will consume a standardized ad libitum breakfast meal during the early follicular phase (days 2-5 of menstrual bleeding). Participants will have 30 minutes to eat as much as they wish, and their consumption will be recorded by a dietitian. The nutrient content of the consumed foods will be analyzed using the Nutrition Information System (BEBIS) software. Blood samples will be collected and visual analogue scala (VAS) will be filled at fasting and at 30, 60, 90, and 120 minutes post-meal. Serum glucose, insulin, glucagon, ghrelin, and incretin hormones will be analyzed using the enzyme-linked immunosorbent analysis (ELISA) method.\n\nData analysis will be performed using SPSS 23.0 via appropriate statistically analysis. Statistical significance is set at p\\\u003C0.05.",[27],[34,155,156,157,158],"16:8 time-restricted feeding","metabolic risk factors","appetite regulation","obesity","2025-09-08",{"date":161,"type":44},"2025-09-10",{"date":163,"type":21},"2025-10-01",{"date":165,"type":21},"2026-07-30",{"name":167,"class":51},"Hacettepe University",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":175,"maxAge":61,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":52},"100605957","effects-of-wet-cupping-on-polycystic-ovary-syndrome-patients-100605957","NCT07169292","Effects of Wet-Cupping on Polycystic Ovary Syndrome Patients","Effects of Wet-Cupping on Polycystic Ovary Syndrome Patients: A Randomized Controlled Trial","Inclusion Criteria\n\n* Female participants.\n* Aged 20 to 40 years.\n* Diagnosed with Polycystic Ovary Syndrome (PCOS) according to the Rotterdam criteria.\n* Willing to participate in the study and provide informed consent.\n* Not using any of the following in the last month: (Hormonal medications for menstruation, Herbal menstrual remedies or Metformin).\n\nExclusion Criteria\n\n* Known diagnosis of uncontrolled thyroid dysfunction.\n* Diagnosis of diabetes mellitus.\n* Elevated FSH levels above 20 mIU\u002FmL.\n* Hyperprolactinemia with serum levels above 1000 mIU\u002FL.\n* Pregnant or lactating women.\n* Known coagulation disorders.\n* Anemia with hemoglobin levels less than 10 g\u002FdL.\n* History of undergoing dry cupping, wet cupping, or acupuncture in the past 6 months.\n* History of surgical removal of both ovaries or the uterus.\n* Other causes of hyperandrogenism, including:\n* Late-onset non-classic 21-hydroxylase deficiency (excluded clinically; lab investigation if clinically indicated).\n* Ovarian androgen-secreting tumors.\n* Use of anabolic or androgenic drugs.\n* Cushing's syndrome.\n* Hypothalamic or pituitary disorders causing amenorrhea.\n* Primary ovarian insufficiency.","20 Years",{"count":123,"type":21},[24],"The goal of this clinical trial is to evaluate whether wet cupping therapy (Hijama) can improve reproductive and metabolic outcomes in women diagnosed with Polycystic Ovary Syndrome (PCOS). This study will be conducted among female participants aged 20-40 years who have been diagnosed with PCOS according to the Rotterdam criteria.\n\nThe main questions it aims to answer are:\n\nCan wet cupping therapy regulate menstrual cycles in women with PCOS?\n\nCan it increase the pregnancy rate in married participants with PCOS-related infertility?\n\nResearchers will compare outcomes between a wet cupping group and a control group to determine whether Hijama has significant effects on reproductive, hormonal, and metabolic markers.\n\nParticipants will:\n\nUndergo screening and eligibility evaluation using a checklist\n\nBe randomized into either the wet cupping (intervention) or control group\n\nReceive lifestyle counseling (diet and physical activity)\n\nFor the intervention group:\n\nReceive one Hijama session performed by a certified practitioner\n\nUndergo follow-up at 4 and 12 weeks for clinical, hormonal, and ultrasound assessments\n\nFor all participants:\n\nComplete laboratory tests, ultrasound scans, and questionnaires on PCOS symptoms and quality of life\n\nReport any side effects during and after the study period",[27],"2025-09-05",{"date":182,"type":44},"2025-09-11",{"date":184,"type":21},"2026-01-01",{"date":186,"type":21},"2026-12-31",{"name":188,"class":51},"Princess Nourah Bint Abdulrahman University",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":18,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":52},"100577100","comparative-study-between-homa1-ir-and-homa2-ir-in-prediction-of-ovulation-outcome-in-women-with-pcos-100577100","NCT06793904","Comparative Study Between HOMA1-IR and HOMA2-IR in Prediction of Ovulation Outcome in Women With PCOS","Comparative Study Between HOMA1-IR and HOMA2-IR in Prediction of Ovulation Outcome in Women With PCOS: A Prospective Cohort Study","Inclusion Criteria:\n\n* Age 18-35 years\n* duration of infertility 1-4 years\n* PCOS\n\nExclusion Criteria:\n\nwomen with other causes of infertility (tubal factor assessed by laparoscopy or hysterosalpingogram, uterine cavity abnormality assessed by ultrasound or hysteroscopy or male factor assessed by seme analysis),\n\n* endometriosis,\n* ovarian cysts,\n* endocrinological abnormalities (Diabetes mellitus, hypothalamic, pituitary or thyroid disorders, or hyperprolactinemia),\n* women with history of poor ovarian response or ovarian hyperstimulation\n* women with chronic diseases, chromosomal, autoimmune or coagulation defects, abnormal leucocytic count or other inflammatory markers\n* Women with contraindications to pregnancy.",{"count":197,"type":21},122,[24],"122 women diagnosed with PCOS seeking fertility in the fertility clinic at kasr Alainy hospital will be subjected to Homeostatic model assessment for insulin resistance 1 was calculated for all participants through the equation \\[glucose (mmol\u002FL) × insulin (µU\u002FL)\\]\u002F22.5 while homeostatic model assessment for insulin resistance 2 was calculated by the HOMA2 calculator. All women will be subjected to induction of ovulation using the Aromatase inhibitor Letrozole 2.5 mg tab twice daily from the 3rd day of the cycle for 5 days . Ultrasound follow up of follicular growth will be performed till dominant follicular size reaches 18-22 mm. FSH preparations will be introduced as needed.",[27],"2025-02-03",{"date":203,"type":44},"2025-02-05",{"date":205,"type":44},"2025-02-01",{"date":207,"type":21},"2026-01",{"name":209,"class":51},"Cairo University",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":61,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":4},"100570955","comparison-of-pregnancy-outcomes-in-women-with-polycystic-ovarian-syndrome-with-and-without-glucophage-100570955","NCT06713967","Comparison of Pregnancy Outcomes in Women with Polycystic Ovarian Syndrome with and Without Glucophage","Comparison of Outcome of Pregnant Females with Polycystic Ovarian Syndrome with or Without Glucophage","Inclusion Criteria:\n\nPregnant females aged 18-40 years Diagnosed with polycystic ovarian syndrome (PCOS) before conception, as per operational definition.\n\nPresent in the 1st trimester at the booking visit. Singleton fetus on booking scan between 5th to 13th week of gestation.\n\nExclusion Criteria:\n\nFemales who do not give informed consent for follow-up. Females with preeclampsia (BP ≥140\u002F90 mmHg with proteinuria \\>+1 on dipstick method).\n\nFemales already diagnosed with gestational diabetes (OGTT \\>186 mg\u002Fdl). Females already taking trial treatment (as per medical record). Twin pregnancy or abnormal placenta (assessed on ultrasound). Diagnosed hypertensives and diabetic patients.",{"count":218,"type":21},70,[24],"The goal of this clinical trial is to learn if Glucophage (metformin) improves pregnancy outcomes in women with polycystic ovarian syndrome (PCOS). It will also evaluate the safety of Glucophage during pregnancy. The main questions it aims to answer are:\n\nDoes Glucophage reduce the risks of early pregnancy loss, preterm delivery, and gestational diabetes? Are there any medical problems associated with taking Glucophage during pregnancy? Researchers will compare Glucophage with standard care (diet and exercise) to see if it improves pregnancy outcomes in women with PCOS.\n\nParticipants will:\n\nTake Glucophage or follow a standard diet and exercise plan throughout pregnancy.\n\nAttend regular follow-up visits for checkups, ultrasounds, and blood tests. Have their pregnancy outcomes, such as fetal growth and gestational diabetes, recorded.",[27,222],"Pregnancy Outcomes","2024-12-03",{"date":225,"type":44},"2024-12-06",{"date":227,"type":21},"2025-02-02",{"date":229,"type":21},"2025-05-26",{"name":231,"class":51},"University of Health Sciences Lahore",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":147,"sex":16,"minAge":240,"maxAge":17,"enrollmentInfo":241,"targetDuration":243,"studyType":244,"phases":4,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":52},"100565488","polycystic-ovarian-syndrome-pcos-biomarker-evaluation-study-100565488","NCT06642831","Polycystic Ovarian Syndrome (PCOS) Biomarker Evaluation Study","Polycystic Ovarian Syndrome (PCOS) in Human Adolescent and Young Adult Females - Biomarker Evaluation Study (PHOEBE)","PHOEBE","Inclusion Criteria:\n\n* Female subjects age 15-25 years\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Less than 1 years from onset of menarche\n* Use of hormonal contraceptives\n* Documented ongoing pregnancy\n* Major ovarian abnormalities, including subject with only one ovary, cysts and solid masses \\> 2 cm as detected by transvaginal ultrasound\n* Malignancy ( documented malignancy, documentation of current radiation therapy or chemotherapy in medical record)","15 Years",{"count":242,"type":21},380,"1 Year","OBSERVATIONAL","The purpose of the study is to validate recently identified biomarkers for the identification of PCOS in adolecent and young adult women.",[27],[95,248,249],"biomarker","adolescents","2024-10-14",{"date":252,"type":44},"2024-10-15",{"date":254,"type":44},"2023-01-31",{"date":256,"type":21},"2027-03",{"name":258,"class":51},"University Hospital Erlangen"]